Cas No.Product NameDescription
1207456-01-6BMN673BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
912444-00-9VeliparibVeliparib is a potent inhibitor of both PARP-1 and PARP-2 by [3H]NAD+ with Kis of 5.2 and 2.9 nmol/L, respectively.
459868-92-9Rucaparib phosphateRucaparib (inhibit parp), ki value at 1.4 nm.
160003-66-7IniparibBSI-201(Iniparib) is a potent PARP1 inhibitor with strong anti-neoplastic effect.
763113-22-0olaparidOlaparib (AZD2281) is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1and PARP-2, respectively.
934162-61-5A-966492A-966492 is one of the most potent PARP inhibitors.
328543-09-5AG14361AG14361 is a potent poly(ADP-ribose) polymerase (PARP-1) inhibitor with a GI50 of 10.9 μM.
344458-19-1PJ-34PJ34 (hydrochloride) is a novel potent specific inhibitor of PARP-l. PJ34 has been reported to enhance chemotherapeutic effects in certain types of tumors.
832714-46-2APD668APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.
1038915-73-9MK-4827 tosylateNiraparib, also known as MK4827, is an orally active, potent and selective poly(ADP-Ribose) polymerase (PARP) inhibitor that radiosensitizes human lung and breast cancer cells. Niraparib inhibits PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM respectively. Niraparib is currently in Phase 3 clinical trials for ovarian cancer and BRCA+ breast cancer.
1038915-64-8MK-4827 hydrochlorideMK-4827(Niraparib) Hcl is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.
923978-27-2ElafibranorElafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor(PPAR)-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.
1262417-51-5NMS-P118NMS-P118 is a potent, orally available, and highly selective PARP-1 Inhibitor.
1140964-99-3 E7449E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway